Cardiomyopathies are characterized by structural changes in the cardiac muscle due to severe extracellular matrix (ECM) remodeling taking place under pathological conditions. Several studies have shown cardiac fibrosis being present in all different types of cardiomyopathies and being associated with a worse prognosis.
Cardiomyopathy patients range from asymptomatic to symptomatic fast progressors. Being able to quantify changes in the ECM turnover early on can be very informative. With the use of highly specific, non-invasive biomarkers targeting extracellular matrix components circulating in the blood, it would be possible to get a great insight into disease progression and influence decision-making.
Please don't hesitate to contact us if you have any questions or other inquiries.